Objective: Epoetin beta pegol (C.E.R.A.) has a long half-life and exerts a more sustained effect on erythropoiesis as compared to epoetin beta. Therefore, the effects of C.E.R.A. on the correction of anemia and iron dynamics are potentially different from those of epoetin beta (EPOβ). We evaluated the state of anemia and the iron dynamics after treatment switch from EPOβ to C.E.R.A. in this clinical study. Subjects: A total of 8 patients undergoing stable maintenance hemodialysis were enrolled. Patients receiving under 4,500 IU/week of EPOβ were switched to C.E.R.A. 100 μg, and those receiving 4,500 IU/week or over of EPOβ were switched to C.E.R.A. 150 μg. Methods: The serum concentrations of erythropoietin (EPO), Fe, TSAT, ferritin and hepcidin-25, and the reticulocyte counts and hemoglobin (Hb) levels were measured on the 2
nd, 4
th, 7
th, 14
th, 21
st and 28
th day after the 1
st intravenous injection, and on the 14
th and 28
th day after the 2
nd and 3
rd intravenous injections and the data were analyzed. Results: While the serum EPO concentrations were significantly higher until the 14
th day (p<0.05), the serum Fe, TSAT and ferritin showed a tendency to become lower from the 7
th day, and the serum hepcidin-25 became significantly lower from the 2
nd day. The levels of each of the serum markers returned to the baseline after the 28
th day. Similar changes of the iron dynamics were observed after the 2
nd and 3
rd injections. Conclusions: Following treatment switch from EPOβ to C.E.R.A., dramatic changes of both the parameters of iron dynamics and hematopoiesis were observed during the 4-week observation period after the treatment switch, and the Hb level was stably maintained for 12 weeks. Based on these findings, we do not recommend routine measurement of the serum markers related to the iron dynamics on the 7
th and/or 14
th day after switching of treatment from EPOβ to C.E.R.A.
View full abstract